Home
  Abstracts
  ASCO Daily News
  About the Meeting
  Attendee Information
  Meeting Program
  Presenter and Faculty Resources
  Exhibitor Information
  Public & Patient Information
  Past Annual Meetings

Abstracts > Trials in Progress Poster Session

Trials in Progress Poster Session

ASCO recognizes the importance of bringing together researchers to discuss ongoing trials. The Trials in Progress poster session provides an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, the Trials in Progress poster session highlights the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice. 

All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion in the Trials in Progress session. Trials submitted to this session are ongoing and have not reached prespecified endpoints for analysis. As such, inclusion of results would be improper and is strictly forbidden.

What is acceptable in a Trials in Progress abstract and poster?

  • Scientific background/rationale for the trial. Preclinical and/or earlier-phase clinical data that has already been publically presented or published may be included with references. The Trials in Progress session should not be used to present preclinical or earlier-phase clinical data for the first time.
  • Trial design and statistical methods, highlighting any novel aspects of the design
  • Treatment or intervention planned
  • Major eligibility criteria, highlighting unusual aspects
  • Correlative studies of particular interest
  • Current enrollment without providing results or endpoints
         
  • Enrollment must have already begun or have been completed with no data analysis available.
  • Phase I studies may say, “Cohorts 1 and 2 have been completed without DLT. Enrollment to cohort 3 began in January 2011.”
  • Phase II studies may report, “8 of planned 32 patients have been enrolled” or “Prespecified activity goal for the first stage of accrual was met; second stage accrual began in January 2011.”
  • Phase III trials may report, “The DMC last reviewed the trial in December 2010 and suggested that the trial continue as planned.”
  • Clinical trial registry number (required)

 

 What is not acceptable in a Trials in Progress abstract and poster session?
 

  • Any preliminary data including toxicity, response rate, PK or correlative analyses. NOTE: Abstracts including results or preliminary data will be rejected without further review.

  • Brand or proprietary drug names

What is the abstract selection process for submitted Trials in Progress abstracts?

Abstracts will be reviewed by the Trials in Progress subcommittee of the ASCO Scientific Program Committee. Abstracts will be evaluated on the strength of the science underlying the trial, novelty of the study design and/or correlatives, potential for collaboration, and overall interest to the ASCO community.
WebsiteFeedback